A carregar...
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
The prognosis for patients with recurrent glioblastomas (GBMs) is dismal, with a median survival of 3–6 months. We performed a phase II trial of low-dose continuous (metronomic) treatment using temozolomide (TMZ) for recurrent GBMs. TMZ-refractory patients with GBM who experienced disease recurrence...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2940595/ https://ncbi.nlm.nih.gov/pubmed/20167817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop030 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|